about
MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitmentObinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.The vestigial enzyme D-dopachrome tautomerase protects the heart against ischemic injury.The outcome of renal ischemia-reperfusion injury is unchanged in AMPK-β1 deficient mice.Critical role for macrophage migration inhibitory factor (MIF) in Ross River virus-induced arthritis and myositis.Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.Macrophage migration inhibitory factor promotes resistance to glucocorticoid treatment in EAE.Macrophage migration inhibitory factor and its role in autoimmune diseases.Macrophage migration inhibitory factor coordinates DNA damage response with the proteasomal control of the cell cycle.MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease.Role of migratory inhibition factor in age-related susceptibility to radiation lung injury via NF-E2-related factor-2 and antioxidant regulationRandomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.Brain miffed by macrophage migration inhibitory factor.Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia.Macrophage-derived, macrophage migration inhibitory factor (MIF) is necessary to induce disease in the K/BxN serum-induced model of arthritis.MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse models.Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.A tautomerase-null macrophage migration-inhibitory factor (MIF) gene knock-in mouse model reveals that protein interactions and not enzymatic activity mediate MIF-dependent growth regulation.Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor.Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity.
P50
Q28298072-88782FB6-9E2B-49F0-A781-AE67DA054052Q33433426-2D09EAD0-E0B6-460D-B8D1-69034E4A7216Q33944140-0DD814B6-C7D6-4DEC-ADFC-D30FEE205E03Q34130765-897843F7-F4DD-41C8-B312-80E57518BCDBQ34197622-9C911BDD-8889-409B-8485-4D17CCB215E9Q35760817-287B25B2-9A3B-47AC-886C-47C7E6A7122BQ35928741-CCFC2CD5-77EC-419D-A566-C00FBDB6E553Q35971265-241AE684-076A-4402-80A9-0BC0229632C3Q36787781-B8987CCF-025A-4D88-9981-99AFF02CB14DQ37280881-4885B2E2-E103-4680-95EF-0AB848608DF2Q37297899-AAA327E2-93DA-4046-AA53-34438B6DF4A2Q37380415-7756BDDA-4443-4231-A14A-7CF585E070F5Q37672472-0BFB3FE8-A668-4DC7-9DDF-88C15AEF2809Q38042932-51F30843-97C5-4D4D-BA48-D53D1B941C3CQ40301879-D00AB80B-A092-4CAC-A601-468668FA6D64Q41837807-DA20C2E1-A084-49F0-9A5A-B939EFBC4DEDQ42425195-D31E856B-6EF7-4F34-B211-DD2D1CCA8FBFQ42643278-D8294E79-9F2B-49B2-A595-F6DC691CD2FBQ43163083-3E15E96E-C832-44F3-B303-34D5C39DA632Q44264861-7EEA5F2C-5686-49E5-864D-4C8F81D0158BQ46669596-250B8948-7E72-4578-B47D-58F25034AFE3
P50
name
Günter Fingerle-Rowson
@ast
Günter Fingerle-Rowson
@en
Günter Fingerle-Rowson
@fr
Günter Fingerle-Rowson
@nl
type
label
Günter Fingerle-Rowson
@ast
Günter Fingerle-Rowson
@en
Günter Fingerle-Rowson
@fr
Günter Fingerle-Rowson
@nl
prefLabel
Günter Fingerle-Rowson
@ast
Günter Fingerle-Rowson
@en
Günter Fingerle-Rowson
@fr
Günter Fingerle-Rowson
@nl